Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749355 | 0.92 | PRCP (0.56) | PRCPALDH1A1KDM4EPDE2APDE3A | |
| SCHEMBL14686430 | 0.91 | PRCP (0.76) | PRCPALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL14749338 | 0.89 | PRCP (0.65) | PRCPALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL12183983 | 0.87 | PRCP (0.64) | PRCPALDH1A1KDM4EKMT2A | |
| SCHEMBL12184064 | 0.87 | PRCP (0.83) | PRCPALDH1A1KDM4EPROKR1 | |
| SCHEMBL14749333 | 0.85 | PRCP (0.59) | PRCPALDH1A1KDM4EPDE2AMAPT | |
| SCHEMBL14749316 | 0.84 | PRCP (0.57) | PRCPALDH1A1KDM4EPDE2APDE3A | |
| SCHEMBL14749332 | 0.83 | PRCP (0.54) | PRCPALDH1A1KDM4EPROKR1POLB | |
| SCHEMBL14749330 | 0.83 | PRCP (0.57) | PRCPALDH1A1PROKR1 | |
| SCHEMBL14749320 | 0.83 | PRCP (0.58) | PRCPALDH1A1KDM4EPDE2APDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885ALDH1A1 661/4885KDM4E 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.